Vaglio et al. (140) found that long-term use of low-dose IL-2 and IFN-α is an effective and well-tolerated treatment choice that can prevent tumor metastasis and extend RFS in low-risk mRCC patients. This evidence concerns the gene IL2 and neoplasm.